Related Experiment Videos
Ciprofloxacin therapy for Mediterranean spotted fever
Antimicrobial Agents and Chemotherapy
|October 1, 1986
Summary
Ciprofloxacin effectively treated Mediterranean spotted fever in five patients. This antimicrobial agent, administered intravenously then orally, led to complete patient recovery, supporting its in vitro efficacy against Rickettsia conorii.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Mediterranean spotted fever is a tick-borne illness caused by Rickettsia conorii.
- Prompt and effective treatment is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of ciprofloxacin in treating Mediterranean spotted fever.
- To assess the clinical correlation between ciprofloxacin's in vitro activity and patient response.
Main Methods:
- A case series involving five patients diagnosed with Mediterranean spotted fever.
- Treatment regimen: intravenous ciprofloxacin for 2 days, followed by oral ciprofloxacin for 8 days.
Main Results:
- All five patients completed the treatment regimen.
- Complete clinical cure was observed in all five patients.
- The results align with previously observed in vitro susceptibility of Rickettsia conorii to ciprofloxacin.
Conclusions:
- Ciprofloxacin demonstrates significant clinical efficacy in treating Mediterranean spotted fever.
- The study supports the use of ciprofloxacin as a treatment option for this infection.
- Further research is warranted to confirm these preliminary findings in larger trials.